{"filing":{"accession_number":"0001140361-26-035979","cik":"0001228627","ticker":"IRD","company_name":"Opus Genetics, Inc.","form":"8-K","filing_date":"2026-09-09","report_date":"2026-09-09","primary_document":"ef20081753_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1228627/000114036126035979/ef20081753_8k.htm"},"events":[{"id":32186,"run_id":29568,"accession_number":"0001140361-26-035979","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Opus Genetics disclosed positive interim clinical trial data from Cohort 1 of its Phase 1/2 BIRD-1 trial of OPGx-BEST1, demonstrating safety (no serious adverse events), efficacy (visual function improvements in all five participants, structural improvements in four), and successful FDA alignment on pivotal trial endpoints. The company is advancing to Cohort 2, representing a material clinical and regulatory milestone for the drug candidate's development trajectory.","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-09-09","form":"8-K","submitted_at":null,"items":[{"id":35297,"accession_number":"0001140361-26-035979","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Opus Genetics disclosed positive clinical trial data from Cohort 1 of its Phase 1/2 trial of OPGx-BEST1, including safety results (no serious adverse events), efficacy outcomes (visual function improvements in all five participants, structural improvements in four), and FDA alignment on pivotal trial endpoints. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's development trajectory and regulatory path forward, but it does not constitute a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:32:02.353582+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35298,"accession_number":"0001140361-26-035979","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive interim clinical trial results from the Phase 1/2 BIRD-1 trial of OPGx-BEST1, including safety and efficacy data from Cohort 1, advancement to Cohort 2, and successful FDA alignment on pivotal trial endpoints. While clinical-stage biotech companies routinely disclose trial progress, this represents a material operational milestone—positive proof-of-concept data, favorable safety profile, and regulatory alignment that directly inform the company's development pathway and commercial prospects. The disclosure does not fit earnings_release (no financial results), material_litigation, or other specific categories, but constitutes a significant operational/clinical development event material to investors assessing the company's pipeline progress and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:32:02.353582+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35297,"accession_number":"0001140361-26-035979","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Opus Genetics disclosed positive clinical trial data from Cohort 1 of its Phase 1/2 trial of OPGx-BEST1, including safety results (no serious adverse events), efficacy outcomes (visual function improvements in all five participants, structural improvements in four), and FDA alignment on pivotal trial endpoints. This is a material operational/clinical milestone for a clinical-stage biopharmaceutical company that would affect investor assessment of the drug candidate's development trajectory and regulatory path forward, but it does not constitute a formal earnings release, M\u0026A activity, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:32:02.353582+00:00","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-09-09"},{"id":35298,"accession_number":"0001140361-26-035979","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This disclosure announces positive interim clinical trial results from the Phase 1/2 BIRD-1 trial of OPGx-BEST1, including safety and efficacy data from Cohort 1, advancement to Cohort 2, and successful FDA alignment on pivotal trial endpoints. While clinical-stage biotech companies routinely disclose trial progress, this represents a material operational milestone—positive proof-of-concept data, favorable safety profile, and regulatory alignment that directly inform the company's development pathway and commercial prospects. The disclosure does not fit earnings_release (no financial results), material_litigation, or other specific categories, but constitutes a significant operational/clinical development event material to investors assessing the company's pipeline progress and probability of success.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-09T11:32:02.353582+00:00","company_name":"Opus Genetics, Inc.","ticker":"IRD","filing_date":"2026-09-09"}]}